About: Oritavancin     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Oritavancin (also known as LY333328) is an investigational glycopeptide antibiotic with bactericidal activity effective in treating infections caused by Gram-positive organisms. The clinical efficacy of oritavancin has not yet been determined. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Citron DM, Kwok YY, Appleman MD: In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic Gram-positive cocci. Anaerobe. 2005 Feb-Apr;11(1-2):93-5. Epub 2004 Dec 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16701537 # Ward KE, Mersfelder TL, LaPlante KL: Oritavancin--an investigational glycopeptide antibiotic. Expert Opin Investig Drugs. 2006 Apr;15(4):417-29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16548791 # Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16495262 # Mercier RC, Hrebickova L: Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther. 2005 Jun;3(3):325-32. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15954849 # Fetterly GJ, Ong CM, Bhavnani SM, Loutit JS, Porter SB, Morello LG, Ambrose PG, Nicolau DP: Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005 Jan;49(1):148-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15616289 # Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15474317 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
  • investigational (en)
http://linked.open...drugbank/halfLife
  • The mean (range) plasma terminal half-life of oritavancin is 195.4 (135.8-273.8) hours across all dose levels from 0.05-0.5 mg/kg. (en)
http://linked.open...ugbank/indication
  • Investigated for use/treatment in bacterial infection and skin infections/disorders. (en)
sameAs
Title
  • Oritavancin (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Oritavancin is a glycopeptide antibiotic. This class of drugs inhibit the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis. They bind to the amino acids within the cell wall preventing the addition of new units to the peptidoglycan. In particular they bind to acyl-D-alanyl-D-alanine in peptidoglycan. (en)
http://linked.open.../drugbank/synonym
  • Chlorobiphenyl-chloroeremomycin (en)
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open.../affectedOrganism
  • Gram-positive Bacteria (en)
  • Streptococcus pneumoniae (en)
  • Streptococcus pyogenes (en)
  • Staphylococcus aureus (en)
  • Enterococcus faecalis (en)
http://linked.open...casRegistryNumber
  • 171099-57-3 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 121 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software